Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1112606.RAYGLH9s0zFwq-0I47Yz-3EH2CKUOgdfu0-SKCvPY--fM130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1112606.RAYGLH9s0zFwq-0I47Yz-3EH2CKUOgdfu0-SKCvPY--fM130_assertion type Assertion NP1112606.RAYGLH9s0zFwq-0I47Yz-3EH2CKUOgdfu0-SKCvPY--fM130_head.
- NP1112606.RAYGLH9s0zFwq-0I47Yz-3EH2CKUOgdfu0-SKCvPY--fM130_assertion description "[Subsequent AMKL evolves from a pre-existing TAM clone through the acquisition of additional mutations, with major mutational targets including multiple cohesin components (53%), CTCF (20%), and EZH2, KANSL1 and other epigenetic regulators (45%), as well as common signaling pathways, such as the JAK family kinases, MPL, SH2B3 (LNK) and multiple RAS pathway genes (47%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1112606.RAYGLH9s0zFwq-0I47Yz-3EH2CKUOgdfu0-SKCvPY--fM130_provenance.
- NP1112606.RAYGLH9s0zFwq-0I47Yz-3EH2CKUOgdfu0-SKCvPY--fM130_assertion evidence source_evidence_literature NP1112606.RAYGLH9s0zFwq-0I47Yz-3EH2CKUOgdfu0-SKCvPY--fM130_provenance.
- NP1112606.RAYGLH9s0zFwq-0I47Yz-3EH2CKUOgdfu0-SKCvPY--fM130_assertion SIO_000772 24056718 NP1112606.RAYGLH9s0zFwq-0I47Yz-3EH2CKUOgdfu0-SKCvPY--fM130_provenance.
- NP1112606.RAYGLH9s0zFwq-0I47Yz-3EH2CKUOgdfu0-SKCvPY--fM130_assertion wasDerivedFrom befree-2016 NP1112606.RAYGLH9s0zFwq-0I47Yz-3EH2CKUOgdfu0-SKCvPY--fM130_provenance.
- NP1112606.RAYGLH9s0zFwq-0I47Yz-3EH2CKUOgdfu0-SKCvPY--fM130_assertion wasGeneratedBy ECO_0000203 NP1112606.RAYGLH9s0zFwq-0I47Yz-3EH2CKUOgdfu0-SKCvPY--fM130_provenance.